Anti-Human CD47 Antibody (Clone: B6H12) | PA007459
$150.00 – $900.00
Recombinant Mouse IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
- Details & Specifications
- References
| Catalog No. | PA007459 |
|---|---|
| Name | Anti-Human CD47 Antibody (Clone: B6H12) | PA007459 |
| Product Name | In vivo Grade Recombinant Anti-Human CD47 Monoclonal Antibody, Mouse IgG1 Kappa (Clone: B6H12) |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | CD47, CD47 antigen, CD47 molecule, CD47 glycoprotein, Integrin associated protein, Integrin-associated protein, Leukocyte surface antigen CD47, MER6, Protein MER6, Rh-related antigen, OA3, IAP |
| Clone | B6H12. |
| Isotype | Mouse IgG1 Kappa. |
| Specificity/Sensitivity | The in vivo grade recombinant mouse monoclonal antibody (clone: B6H12) specifically binds to mouse CD47. |
| Applications | ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD47 protein. |
| Form Of Antibody | 0.2 μM filtered solution of 1x PBS. |
| Endotoxin | Less than 1 EU/mg of protein as determined by LAL method. |
| Purity | >95% by SDS-PAGE under reducing conditions. |
| Shipping | The in vivo grade recombinant anti-human CD47 antibodies (clone of B6H12) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Note | Recombinant Mouse IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator. |
| Order Offline | Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card. |
Description
PA007459: Recombinant Anti-Human CD47 Monoclonal Antibody(Clone: B6H12), Mouse IgG1 Kappa, In vivo Grade
The in vivo grade recombinant anti-human CD47 Mouse IgG1 Kappa monoclonal antibody was produced in mammalian cells.
References of Anti-Human CD47 Monoclonal Antibody (Clone: B6H12)
1. Tumor-selective Blockade of CD47 Signaling with CD47 Antibody for Enhanced Anti-tumor Activity in Malignant Meningioma
Wang, Y., et al.Mol Ther. 2023 May 3;31(5):1321-1335. doi: 10.1016/j.ymthe.2023.03.012. PMID: 37171006
“The anti-CD47 antibody B6H12 suppressed tumor cell growth, motility, and enhanced macrophage-mediated phagocytosis in IOMM-Lee meningioma cells in vitro. In vivo, B6H12 or MIAP301 significantly inhibited tumor growth in NSG mice, with effects partially blocked by macrophage depletion. Combination with dinutuximab and aNK cells enhanced neuroblastoma xenograft regression, as shown by wound healing and transwell invasion assays.”
2. CD47 Blocking Antibody Enhances Biodegradable PLGA and Naked DNA Vaccine Induced T Cell Responses in a Murine Model of HPV16+ Tumor
Li, X., et al.Front Immunol. 2023 Apr 13;14:1163618. doi: 10.3389/fimmu.2023.1163618. PMID: 37075968
“B6H12, administered intraperitoneally at 200 µg per mouse, enhanced immune responses in HPV16+ TC-1 tumor-bearing C57BL/6 mice. Combined with a PLGA-based DNA vaccine, it significantly increased CD8+ T cell infiltration and IFN-γ production in tumors, as measured by ELISPOT assays, with tumor volume monitored every 3 days using calipers.”
3. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer
Liu, Y., et al.Oncotarget. 2016 Feb 29;7(9):10148-67. doi: 10.18632/oncotarget.7308. PMID: 26840086
“The anti-CD47 antibody B6H12, administered at 10 mg/kg twice weekly via intraperitoneal injection, inhibited tumor growth in MDA-MB-231 triple-negative breast cancer xenografts in NSG mice by preventing SIRPα engagement. Immunohistochemistry confirmed reduced EGFR phosphorylation, indicating suppression of stem cell and EGF signaling.”
4. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Sockolosky, J. T., et al.Nat Med. 2015 Oct;21(10):1126-33. doi: 10.1038/nm.3931. PMID: 26259518
“In vivo administration of B6H12 at 250 µg per mouse every other day for 2 weeks led to significant tumor regression in C57BL/6 mice with B16F10 melanoma. Increased tumor-infiltrating CD8+ T cells were observed, with therapeutic effects abrogated by CD8+ T cell depletion, confirming T cell dependency.”
5. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia
Chao, M. P., et al.Cancer Res. 2010 Dec 15;70(24):10182-90. doi: 10.1158/0008-5472.CAN-10-2238. PMID: 21163924
“B6H12, administered at 100 µg per mouse daily, significantly reduced leukemia burden in bone marrow of NOD/SCID mice engrafted with 1 × 10^6 primary ALL cells via tail vein. Flow cytometry confirmed depletion of CD47+ leukemic cells, and survival was significantly prolonged compared to controls.”
For more technical references or data sheets regarding the Recombinant Anti-Human CD47 Monoclonal Antibody (Clone: B6H12) formats, please contact our scientific support team at message@sydlabs.com.
Related Recombinant IgG Reference Antibodies:
Recombinant mouse IgG1 isotype control antibody, In vivo Grade
Anti-Human CD47 (B6H12) from: Anti-Human CD47 Monoclonal Antibody, Mouse IgG1 Kappa (Clone: B6H12): PA007459 Syd Labs
You may also like…
- Select optionsQuick View
- Select optionsQuick View